8-K 1 dhoap604.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2004 HEMACARE CORPORATION (Exact name of registrant as specified in its charter) California (State or other jurisdiction of incorporation) 000-15223 95-3280412 (Commission File No.) (I.R.S. Employer Identification No.) 21101 Oxnard Street Woodland Hills, CA 91367 (Address of principal executive offices)(Zip Code) Registrant's telephone number, including area code: (818) 226- 1968 -1- 2 ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE The text of a press release dated June 17, 2004, issued by HemaCare Corporation ("HemaCare") announcing an investigational site agreement with Otsuka America Pharmaceutical and the termination of a blood center management contract with Dartmouth Hitchcock Hospital, is attached as Exhibit 99.1 hereto and is incorporated by reference herein. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits Exhibit Number Description -------------- ------------------------------------------------ 99.1 Press Release issued by HemaCare, dated June 17, 2004 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2004 HEMACARE CORPORATION By: /s/ Judi Irving __________________________ Judi Irving, Chief Executive Officer -2- 3 EXHIBIT INDEX Exhibit Number Description -------------- --------------------------------------------- 99.1 Press Release issued by HemaCare, dated June 17, 2004 -3-